Premium
Individualization of patients for adjuvant chemotherapy after surgical treatment of cervical cancer
Author(s) -
UEKI M.,
OKAMURA S.,
MAEDA T.
Publication year - 1987
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1987.tb02274.x
Subject(s) - medicine , chemotherapy , cervical cancer , adjuvant , adjuvant chemotherapy , surgery , risk factor , adjuvant therapy , oncology , cancer , breast cancer
Summary. Adjuvant chemotherapy using Tegafur (l‐(2‐tctra hydrofuryl)‐5‐fluorouracil) was given to 52 of 216 patients with recurrence risk of cervical cancer after primary surgical treatment, the degree of risk of recurrence having been formulated as a discriminant function by computer analysis of risk factors involved in disease recurrence. Using the formula, we have managed outpatients in three groups—no recurrence and recurrence after, and before 5 years. Under existing circumstances the power of the discriminant function we have achieved is not yet entirely satisfactory although clinically of value in patient management. Oral, long‐term adjuvant chemotherapy in risk groups was of value, with a 37.4% instantaneous recurrence rate and mild side‐effects. An instantaneous recurrence rate of 37.4% signifies that the recurrence rate in the group of patients given chemotherapy would be 37.4% if it were 100% in the patients not so treated—an improvement factor of just less than 3.